Does Levofloxacin Induce Hemolytic Uremic Syndrome in Patients Infected with Verotoxin-Producing Escherichia coli O157 Infections?
Fifteen Japanese colitis patients, aged above 16 years old, infected with verotoxin-producing Escherichia coli O157 (VTEC O157) were divided into 2 treatment groups. Of the 15 patients, 6 (mean ± SD, 41.3 ± 19.0 years old) were treated with levofloxacin (LVFX), while the remaining 9 patients (32.0 ±...
Gespeichert in:
| Veröffentlicht in: | Japanese Journal of Infectious Diseases 2012, Vol.65(5), pp.442-443 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 443 |
|---|---|
| container_issue | 5 |
| container_start_page | 442 |
| container_title | Japanese Journal of Infectious Diseases |
| container_volume | 65 |
| creator | Ohnishi, Kenji Nakamura-Uchiyama, Fukumi |
| description | Fifteen Japanese colitis patients, aged above 16 years old, infected with verotoxin-producing Escherichia coli O157 (VTEC O157) were divided into 2 treatment groups. Of the 15 patients, 6 (mean ± SD, 41.3 ± 19.0 years old) were treated with levofloxacin (LVFX), while the remaining 9 patients (32.0 ± 10.0 years old) were not treated with any antimicrobial agents. All patients complained of abdominal pain and bloody stool and were not administered antidiarrheals. Hemolytic uremic syndrome (HUS) did not develop in any of the 6 patients treated with LVFX, but developed in 1 of the 9 patients not treated with antimicrobial agents. No statistical difference was found in the occurrence rate of HUS between LVFX-treated patients and patients not treated with antimicrobial agents. Our results suggest that oral administration of LVFX is not associated with risk of HUS in hemorrhagic colitis patients aged above 16 years infected with VTEC O157. |
| doi_str_mv | 10.7883/yoken.65.442 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1534853151</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1069205585</sourcerecordid><originalsourceid>FETCH-LOGICAL-c508t-aad73752848c86cfa86b9893329a3b08d3f1f14f9c6a4873a580d7ba6af5e8033</originalsourceid><addsrcrecordid>eNqF0T1vFDEQBmALEZHkoKNGLinYi7_XW0UoJCTSSYkEoV35vOOcw64dbB_kWn45Jnc5SqoZaZ55mxeht5TMW635ySZ-hzBXci4Ee4GOqNaiYZqrl3XnQjSKE3GIjnO-J4RJSckrdMhY1ynG2BH6_SlCxgv4Gd0YH431AV-FYW0BX8IUx03xFt8mmOr4sglDihPgam5M8RBKrtiBLTDgX76s8DdIscRHH5qbFGuKD3f4PNsVJG9X3mAbR4-vqWx3fz6GfPoaHTgzZnizmzN0e3H-9eyyWVx_vjr7uGisJLo0xgwtbyXTQlutrDNaLTvdcc46w5dED9xRR4XrrDJCt9xITYZ2aZRxEjThfIbeb3MfUvyxhlz6yWcL42gCxHXuqeRCS04l_T8lqmNEyspn6MOW2hRzTuD6h-QnkzYV9X8L6p8K6pXsa0GVv9slr5cTDHv83EgFp1twn4u5gz0wqVYxwr80uYvcX-zKpB4C_wPA7qTr</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1069205585</pqid></control><display><type>article</type><title>Does Levofloxacin Induce Hemolytic Uremic Syndrome in Patients Infected with Verotoxin-Producing Escherichia coli O157 Infections?</title><source>J-STAGE (Free - Japanese)</source><source>MEDLINE</source><source>EZB Electronic Journals Library</source><creator>Ohnishi, Kenji ; Nakamura-Uchiyama, Fukumi</creator><creatorcontrib>Ohnishi, Kenji ; Nakamura-Uchiyama, Fukumi</creatorcontrib><description>Fifteen Japanese colitis patients, aged above 16 years old, infected with verotoxin-producing Escherichia coli O157 (VTEC O157) were divided into 2 treatment groups. Of the 15 patients, 6 (mean ± SD, 41.3 ± 19.0 years old) were treated with levofloxacin (LVFX), while the remaining 9 patients (32.0 ± 10.0 years old) were not treated with any antimicrobial agents. All patients complained of abdominal pain and bloody stool and were not administered antidiarrheals. Hemolytic uremic syndrome (HUS) did not develop in any of the 6 patients treated with LVFX, but developed in 1 of the 9 patients not treated with antimicrobial agents. No statistical difference was found in the occurrence rate of HUS between LVFX-treated patients and patients not treated with antimicrobial agents. Our results suggest that oral administration of LVFX is not associated with risk of HUS in hemorrhagic colitis patients aged above 16 years infected with VTEC O157.</description><identifier>ISSN: 1344-6304</identifier><identifier>EISSN: 1884-2836</identifier><identifier>DOI: 10.7883/yoken.65.442</identifier><identifier>PMID: 22996222</identifier><language>eng</language><publisher>Japan: National Institute of Infectious Diseases, Japanese Journal of Infectious Diseases Editorial Committee</publisher><subject>Administration, Oral ; Adult ; Anti-Bacterial Agents - administration & dosage ; Anti-Bacterial Agents - adverse effects ; Colitis - drug therapy ; Colitis - microbiology ; Escherichia coli ; Escherichia coli Infections - complications ; Escherichia coli Infections - drug therapy ; Escherichia coli O157 - isolation & purification ; Escherichia coli O157 - metabolism ; Female ; Hemolytic-Uremic Syndrome - chemically induced ; Hemolytic-Uremic Syndrome - etiology ; Hemolytic-Uremic Syndrome - microbiology ; Humans ; Japan ; Levofloxacin ; Male ; Middle Aged ; Ofloxacin - administration & dosage ; Ofloxacin - adverse effects ; Retrospective Studies ; Risk Factors ; Shiga Toxins - biosynthesis</subject><ispartof>Japanese Journal of Infectious Diseases, 2012, Vol.65(5), pp.442-443</ispartof><rights>Authors</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c508t-aad73752848c86cfa86b9893329a3b08d3f1f14f9c6a4873a580d7ba6af5e8033</citedby><cites>FETCH-LOGICAL-c508t-aad73752848c86cfa86b9893329a3b08d3f1f14f9c6a4873a580d7ba6af5e8033</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,1883,4024,27923,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22996222$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ohnishi, Kenji</creatorcontrib><creatorcontrib>Nakamura-Uchiyama, Fukumi</creatorcontrib><title>Does Levofloxacin Induce Hemolytic Uremic Syndrome in Patients Infected with Verotoxin-Producing Escherichia coli O157 Infections?</title><title>Japanese Journal of Infectious Diseases</title><addtitle>Jpn J Infect Dis</addtitle><description>Fifteen Japanese colitis patients, aged above 16 years old, infected with verotoxin-producing Escherichia coli O157 (VTEC O157) were divided into 2 treatment groups. Of the 15 patients, 6 (mean ± SD, 41.3 ± 19.0 years old) were treated with levofloxacin (LVFX), while the remaining 9 patients (32.0 ± 10.0 years old) were not treated with any antimicrobial agents. All patients complained of abdominal pain and bloody stool and were not administered antidiarrheals. Hemolytic uremic syndrome (HUS) did not develop in any of the 6 patients treated with LVFX, but developed in 1 of the 9 patients not treated with antimicrobial agents. No statistical difference was found in the occurrence rate of HUS between LVFX-treated patients and patients not treated with antimicrobial agents. Our results suggest that oral administration of LVFX is not associated with risk of HUS in hemorrhagic colitis patients aged above 16 years infected with VTEC O157.</description><subject>Administration, Oral</subject><subject>Adult</subject><subject>Anti-Bacterial Agents - administration & dosage</subject><subject>Anti-Bacterial Agents - adverse effects</subject><subject>Colitis - drug therapy</subject><subject>Colitis - microbiology</subject><subject>Escherichia coli</subject><subject>Escherichia coli Infections - complications</subject><subject>Escherichia coli Infections - drug therapy</subject><subject>Escherichia coli O157 - isolation & purification</subject><subject>Escherichia coli O157 - metabolism</subject><subject>Female</subject><subject>Hemolytic-Uremic Syndrome - chemically induced</subject><subject>Hemolytic-Uremic Syndrome - etiology</subject><subject>Hemolytic-Uremic Syndrome - microbiology</subject><subject>Humans</subject><subject>Japan</subject><subject>Levofloxacin</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Ofloxacin - administration & dosage</subject><subject>Ofloxacin - adverse effects</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>Shiga Toxins - biosynthesis</subject><issn>1344-6304</issn><issn>1884-2836</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqF0T1vFDEQBmALEZHkoKNGLinYi7_XW0UoJCTSSYkEoV35vOOcw64dbB_kWn45Jnc5SqoZaZ55mxeht5TMW635ySZ-hzBXci4Ee4GOqNaiYZqrl3XnQjSKE3GIjnO-J4RJSckrdMhY1ynG2BH6_SlCxgv4Gd0YH431AV-FYW0BX8IUx03xFt8mmOr4sglDihPgam5M8RBKrtiBLTDgX76s8DdIscRHH5qbFGuKD3f4PNsVJG9X3mAbR4-vqWx3fz6GfPoaHTgzZnizmzN0e3H-9eyyWVx_vjr7uGisJLo0xgwtbyXTQlutrDNaLTvdcc46w5dED9xRR4XrrDJCt9xITYZ2aZRxEjThfIbeb3MfUvyxhlz6yWcL42gCxHXuqeRCS04l_T8lqmNEyspn6MOW2hRzTuD6h-QnkzYV9X8L6p8K6pXsa0GVv9slr5cTDHv83EgFp1twn4u5gz0wqVYxwr80uYvcX-zKpB4C_wPA7qTr</recordid><startdate>2012</startdate><enddate>2012</enddate><creator>Ohnishi, Kenji</creator><creator>Nakamura-Uchiyama, Fukumi</creator><general>National Institute of Infectious Diseases, Japanese Journal of Infectious Diseases Editorial Committee</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7QL</scope><scope>C1K</scope></search><sort><creationdate>2012</creationdate><title>Does Levofloxacin Induce Hemolytic Uremic Syndrome in Patients Infected with Verotoxin-Producing Escherichia coli O157 Infections?</title><author>Ohnishi, Kenji ; Nakamura-Uchiyama, Fukumi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c508t-aad73752848c86cfa86b9893329a3b08d3f1f14f9c6a4873a580d7ba6af5e8033</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Administration, Oral</topic><topic>Adult</topic><topic>Anti-Bacterial Agents - administration & dosage</topic><topic>Anti-Bacterial Agents - adverse effects</topic><topic>Colitis - drug therapy</topic><topic>Colitis - microbiology</topic><topic>Escherichia coli</topic><topic>Escherichia coli Infections - complications</topic><topic>Escherichia coli Infections - drug therapy</topic><topic>Escherichia coli O157 - isolation & purification</topic><topic>Escherichia coli O157 - metabolism</topic><topic>Female</topic><topic>Hemolytic-Uremic Syndrome - chemically induced</topic><topic>Hemolytic-Uremic Syndrome - etiology</topic><topic>Hemolytic-Uremic Syndrome - microbiology</topic><topic>Humans</topic><topic>Japan</topic><topic>Levofloxacin</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Ofloxacin - administration & dosage</topic><topic>Ofloxacin - adverse effects</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>Shiga Toxins - biosynthesis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ohnishi, Kenji</creatorcontrib><creatorcontrib>Nakamura-Uchiyama, Fukumi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>Japanese Journal of Infectious Diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ohnishi, Kenji</au><au>Nakamura-Uchiyama, Fukumi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Does Levofloxacin Induce Hemolytic Uremic Syndrome in Patients Infected with Verotoxin-Producing Escherichia coli O157 Infections?</atitle><jtitle>Japanese Journal of Infectious Diseases</jtitle><addtitle>Jpn J Infect Dis</addtitle><date>2012</date><risdate>2012</risdate><volume>65</volume><issue>5</issue><spage>442</spage><epage>443</epage><pages>442-443</pages><issn>1344-6304</issn><eissn>1884-2836</eissn><abstract>Fifteen Japanese colitis patients, aged above 16 years old, infected with verotoxin-producing Escherichia coli O157 (VTEC O157) were divided into 2 treatment groups. Of the 15 patients, 6 (mean ± SD, 41.3 ± 19.0 years old) were treated with levofloxacin (LVFX), while the remaining 9 patients (32.0 ± 10.0 years old) were not treated with any antimicrobial agents. All patients complained of abdominal pain and bloody stool and were not administered antidiarrheals. Hemolytic uremic syndrome (HUS) did not develop in any of the 6 patients treated with LVFX, but developed in 1 of the 9 patients not treated with antimicrobial agents. No statistical difference was found in the occurrence rate of HUS between LVFX-treated patients and patients not treated with antimicrobial agents. Our results suggest that oral administration of LVFX is not associated with risk of HUS in hemorrhagic colitis patients aged above 16 years infected with VTEC O157.</abstract><cop>Japan</cop><pub>National Institute of Infectious Diseases, Japanese Journal of Infectious Diseases Editorial Committee</pub><pmid>22996222</pmid><doi>10.7883/yoken.65.442</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1344-6304 |
| ispartof | Japanese Journal of Infectious Diseases, 2012, Vol.65(5), pp.442-443 |
| issn | 1344-6304 1884-2836 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1534853151 |
| source | J-STAGE (Free - Japanese); MEDLINE; EZB Electronic Journals Library |
| subjects | Administration, Oral Adult Anti-Bacterial Agents - administration & dosage Anti-Bacterial Agents - adverse effects Colitis - drug therapy Colitis - microbiology Escherichia coli Escherichia coli Infections - complications Escherichia coli Infections - drug therapy Escherichia coli O157 - isolation & purification Escherichia coli O157 - metabolism Female Hemolytic-Uremic Syndrome - chemically induced Hemolytic-Uremic Syndrome - etiology Hemolytic-Uremic Syndrome - microbiology Humans Japan Levofloxacin Male Middle Aged Ofloxacin - administration & dosage Ofloxacin - adverse effects Retrospective Studies Risk Factors Shiga Toxins - biosynthesis |
| title | Does Levofloxacin Induce Hemolytic Uremic Syndrome in Patients Infected with Verotoxin-Producing Escherichia coli O157 Infections? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T08%3A38%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Does%20Levofloxacin%20Induce%20Hemolytic%20Uremic%20Syndrome%20in%20Patients%20Infected%20with%20Verotoxin-Producing%20Escherichia%20coli%20O157%20Infections?&rft.jtitle=Japanese%20Journal%20of%20Infectious%20Diseases&rft.au=Ohnishi,%20Kenji&rft.date=2012&rft.volume=65&rft.issue=5&rft.spage=442&rft.epage=443&rft.pages=442-443&rft.issn=1344-6304&rft.eissn=1884-2836&rft_id=info:doi/10.7883/yoken.65.442&rft_dat=%3Cproquest_cross%3E1069205585%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1069205585&rft_id=info:pmid/22996222&rfr_iscdi=true |